Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Korro Bio, a clinical-stage biopharmaceutical company focused on developing genetic medicines through RNA editing, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place on Monday, January 13, 2025, at 3:45 p.m. PT (6:45 p.m. ET) at the Westin St. Francis in San Francisco.
Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the conference. Other key executives, including Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate.
A live webcast of the presentation will be available on the “Events & Presentations” page in the Investor section of Korro’s website (www.korrobio.com). A replay of the event will be accessible for 30 days following the presentation.
Korro Bio, un’azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di medicinali genetici attraverso la modifica dell’RNA, ha annunciato la sua partecipazione al 43° Annuale J.P. Morgan Healthcare Conference. L’evento si svolgerà lunedì 13 gennaio 2025, alle 15:45 PT (18:45 ET) presso il Westin St. Francis di San Francisco.
Ram Aiyar, Ph.D., Amministratore Delegato e Presidente, presenterà alla conferenza. Altri dirigenti chiave, tra cui Vineet Agarwal, Direttore Finanziario, e Kemi Olugemo, M.D., FAAN, Direttore Medico, parteciperanno anch’essi.
Una trasmissione in diretta della presentazione sarà disponibile nella sezione “Eventi & Presentazioni” nella pagina per gli investitori del sito web di Korro (www.korrobio.com). Una registrazione dell’evento sarà accessibile per 30 giorni dopo la presentazione.
Korro Bio, una compañía biofarmacéutica en etapa clínica enfocada en desarrollar medicamentos genéticos a través de la edición de ARN, anunció su participación en la 43ª Conferencia Anual de Atención Médica de J.P. Morgan. El evento se llevará a cabo el lunes 13 de enero de 2025, a las 3:45 p.m. PT (6:45 p.m. ET) en el Westin St. Francis en San Francisco.
Ram Aiyar, Ph.D., Director Ejecutivo y Presidente, presentará en la conferencia. Otros ejecutivos clave, incluidos Vineet Agarwal, Director Financiero, y Kemi Olugemo, M.D., FAAN, Directora Médica, también participarán.
Una transmisión en vivo de la presentación estará disponible en la página de “Eventos & Presentaciones” en la sección de Inversores del sitio web de Korro (www.korrobio.com). Una repetición del evento estará accesible durante 30 días tras la presentación.
Korro Bio는 RNA 편집을 통해 유전자 치료제를 개발하는 데 집중하는 임상 단계의 생명공학 회사로, 제43회 J.P. Morgan 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 이 행사는 2025년 1월 13일 월요일 오후 3시 45분 PT (오후 6시 45분 ET)에 샌프란시스코의 Westin St. Francis에서 열립니다.
Ram Aiyar, Ph.D. 최고 경영자 겸 사장이 컨퍼런스에서 발표할 예정입니다. Vineet Agarwal 최고 재무 책임자와 Kemi Olugemo, M.D., FAAN 최고 의료 책임자 등 다른 주요 경영진들도 참석할 예정입니다.
발표의 실시간 웹캐스트는 Korro 웹사이트의 투자자 섹션에 있는 “이벤트 및 발표” 페이지에서 볼 수 있습니다 (www.korrobio.com). 이벤트의 재생은 발표 후 30일간 이용 가능할 것입니다.
Korro Bio, une entreprise biopharmaceutique en phase clinique axée sur le développement de médicaments génétiques par le biais de l'édition de l'ARN, a annoncé sa participation à la 43e Conférence Annuelle de J.P. Morgan sur la Santé. L'événement aura lieu le lundi 13 janvier 2025, à 15h45 PT (18h45 ET) au Westin St. Francis à San Francisco.
Ram Aiyar, Ph.D., directeur général et président, interviendra lors de la conférence. D'autres dirigeants clés, dont Vineet Agarwal, directeur financier, et Kemi Olugemo, M.D., FAAN, directeur médical, seront également présents.
Une diffusion en direct de la présentation sera disponible sur la page “Événements & Présentations” dans la section Investisseurs du site Web de Korro (www.korrobio.com). Un enregistrement de l'événement sera accessible pendant 30 jours suivant la présentation.
Korro Bio, ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung genetischer Medikamente durch RNA-Bearbeitung spezialisiert hat, gab seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference bekannt. Die Veranstaltung findet am Montag, den 13. Januar 2025, um 15:45 Uhr PT (18:45 Uhr ET) im Westin St. Francis in San Francisco statt.
Ram Aiyar, Ph.D., Geschäftsführer und Präsident, wird auf der Konferenz präsentieren. Weitere wichtige Führungskräfte, darunter Vineet Agarwal, Finanzvorstand, und Kemi Olugemo, M.D., FAAN, medizinische Direktorin, werden ebenfalls teilnehmen.
Ein Live-Stream der Präsentation wird auf der Seite „Veranstaltungen & Präsentationen“ im Investor-Bereich der Korro-Website verfügbar sein (www.korrobio.com). Eine Wiederholung der Veranstaltung wird 30 Tage nach der Präsentation zugänglich sein.
- None.
- None.
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 3:45 p.m. PT (6:45 p.m. ET) at the Westin St. Francis in San Francisco. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also be participating at the conference.
A live webcast of the presentation can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the event will be available for 30 days.
About Korro
Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investor & Media Contact
Tim Palmer
IR@korrobio.com
FAQ
When will Korro Bio present at the J.P. Morgan Healthcare Conference?
Who from Korro Bio will present at the J.P. Morgan Healthcare Conference?
What is the significance of Korro Bio's presentation at the J.P. Morgan Healthcare Conference?
Where can I watch the Korro Bio presentation live?
How long will the replay of Korro Bio's presentation be available?
Who are the other key executives from Korro Bio attending the J.P. Morgan Healthcare Conference?
